TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Yoga as a Complex Intervention for Vets With Stroke
Brief Summary: Approximately 780,000 people suffer a stroke annually in the United States; 200,000 are recurrent strokes. The 17,000 veterans who suffer a stroke yearly are at great risk for a second stroke and therefore should be targeted for stroke risk factor management and prevention interventions.

Balance and fear of falling negatively impact activity and function. Decreased activity and blood pressure (BP) are important modifiable stroke risk factors. These can be addressed through a yoga exercise intervention. Yoga, like tai-chi, is old world alternative medicine that has the potential to greatly impact the lives of older adults.


Options:
A: Arm Label: Arm 1: Yoga Group; Type: EXPERIMENTAL; Interventions: Other: Yoga focused on strength, flexibility, and balance | Arm Label: Arm 2: Yoga Group Plus; Type: EXPERIMENTAL; Interventions: Other: Yoga focused on strength, flexibility, and balance | Arm Label: Arm 3: Wait list control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Yoga focused on strength, flexibility, and balance; Assigned to Arm(s): Arm 1: Yoga Group, Arm 2: Yoga Group Plus
B: Arm Label: Tai chi program via Telerehabilitation; Type: EXPERIMENTAL; Interventions: Behavioral: Tai Chi based exercise program | Arm Label: Tai chi program via home visits; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Tai Chi based exercise program | Intervention Type: BEHAVIORAL; Name: Tai Chi based exercise program; Assigned to Arm(s): Tai chi program via Telerehabilitation, Tai chi program via home visits
C: Arm Label: PREVENT program; Type: EXPERIMENTAL; Interventions: Behavioral: PREVENT program | Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual Care | Intervention Type: BEHAVIORAL; Name: PREVENT program; Assigned to Arm(s): PREVENT program | Intervention Type: BEHAVIORAL; Name: Usual Care; Assigned to Arm(s): Usual Care
D: Arm Label: Intervention arm; Type: EXPERIMENTAL; Interventions: Behavioral: Instruction in physical training program | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Instruction in physical training program; Assigned to Arm(s): Intervention arm

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Strategic Use of New Generation Antidepressants for Depression
Brief Summary: The purpose of the study is to establish the optimum treatment strategy for first-line and second-line antidepressants in the acute phase treatment of major depression.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Antidepressant + placebo | Arm Label: Cariprazine 0.1 - 0.3 mg; Type: EXPERIMENTAL; Interventions: Drug: Antidepressant + cariprazine (0.1-0.3 mg/day) | Arm Label: Cariprazine 1.0 - 2.0 mg; Type: EXPERIMENTAL; Interventions: Drug: Antidepressant + cariprazine (1-2 mg/d) | Intervention Type: DRUG; Name: Antidepressant + placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Antidepressant + cariprazine (0.1-0.3 mg/day); Assigned to Arm(s): Cariprazine 0.1 - 0.3 mg | Intervention Type: DRUG; Name: Antidepressant + cariprazine (1-2 mg/d); Assigned to Arm(s): Cariprazine 1.0 - 2.0 mg
B: Arm Label: Placebo + ADT Lead-in; Type: OTHER; Interventions: Drug: Placebo, Drug: Antidepressant Therapy (ADT) | Arm Label: Placebo + ADT (Double-Blind); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Antidepressant Therapy (ADT) | Arm Label: Cariprazine + ADT (Double-Blind); Type: EXPERIMENTAL; Interventions: Drug: Cariprazine, Drug: Antidepressant Therapy (ADT) | Arm Label: Placebo + ADT (Continued Treatment); Type: OTHER; Interventions: Drug: Placebo, Drug: Antidepressant Therapy (ADT) | Intervention Type: DRUG; Name: Cariprazine; Assigned to Arm(s): Cariprazine + ADT (Double-Blind) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + ADT (Continued Treatment), Placebo + ADT (Double-Blind), Placebo + ADT Lead-in | Intervention Type: DRUG; Name: Antidepressant Therapy (ADT); Assigned to Arm(s): Cariprazine + ADT (Double-Blind), Placebo + ADT (Continued Treatment), Placebo + ADT (Double-Blind), Placebo + ADT Lead-in
C: Arm Label: Continue sertraline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sertraline | Arm Label: Augment with mirtazapine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sertraline, Drug: Mirtazapine | Arm Label: Switch to mirtazapine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mirtazapine | Intervention Type: DRUG; Name: Sertraline; Assigned to Arm(s): Augment with mirtazapine, Continue sertraline | Intervention Type: DRUG; Name: Mirtazapine; Assigned to Arm(s): Augment with mirtazapine, Switch to mirtazapine
D: Intervention Type: DRUG; Name: Olanzapine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Fluoxetine; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness of the Paediatric Electronic Quality of Life Instrument for Childhood Asthma in the Netherlands (Pelican) in Medical Care.
Brief Summary: The objective of this project is to establish the effectiveness of implementation of a self-administered electronic asthma-specific quality of life instrument for childhood asthma in primary care and specialist care.


Options:
A: Arm Label: Facilitator-Led; Type: ACTIVE_COMPARATOR; Interventions: Other: Asthma Shared Decision Making (SDM) Toolkit | Arm Label: Traditional; Type: ACTIVE_COMPARATOR; Interventions: Other: Asthma Shared Decision Making (SDM) Toolkit | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Asthma Shared Decision Making (SDM) Toolkit; Assigned to Arm(s): Facilitator-Led, Traditional
B: Arm Label: Patient decision aids; Type: EXPERIMENTAL; Interventions: Other: Patient decision aid | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Patient decision aid; Assigned to Arm(s): Patient decision aids
C: Arm Label: usual primary care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: PELICAN Primary care; Type: EXPERIMENTAL; Interventions: Other: PELICAN Primary Care | Arm Label: usual secondary care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: PELICAN Secondary Care; Type: EXPERIMENTAL; Interventions: Other: PELICAN Secondary Care | Intervention Type: OTHER; Name: PELICAN Primary Care; Assigned to Arm(s): PELICAN Primary care | Intervention Type: OTHER; Name: PELICAN Secondary Care; Assigned to Arm(s): PELICAN Secondary Care
D: Intervention Type: BEHAVIORAL; Name: Shared-Decision Making; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: ASPIS-Austrian Polyintervention Study to Prevent Cognitive Decline After Ischemic Stroke
Brief Summary: Aim of this randomized controlled study is to test if intensive polyintervention therapy including life style modifications targeting at reduction of modifiable risk factors of stroke can reduce the risk of post-stroke cognitive decline compared to a group of patients receiving standard care.


Options:
A: Arm Label: Cognitive-Oriented Strategy Augmented Rehabilitation (COSTAR); Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive-Oriented Strategy Augmented Rehabilitation (COSTAR) | Arm Label: Task Specific Training (TST); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Task Specific Training (TST) | Intervention Type: BEHAVIORAL; Name: Cognitive-Oriented Strategy Augmented Rehabilitation (COSTAR); Assigned to Arm(s): Cognitive-Oriented Strategy Augmented Rehabilitation (COSTAR) | Intervention Type: BEHAVIORAL; Name: Task Specific Training (TST); Assigned to Arm(s): Task Specific Training (TST)
B: Arm Label: Motivation and lifestyle intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Motivation and lifestyle intervention | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Motivation and lifestyle intervention; Assigned to Arm(s): Motivation and lifestyle intervention
C: Arm Label: CO-OP; Type: EXPERIMENTAL; Interventions: Behavioral: CO-OP | Arm Label: Standard Occupational Therapy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard Occupational Therapy | Intervention Type: BEHAVIORAL; Name: CO-OP; Assigned to Arm(s): CO-OP | Intervention Type: BEHAVIORAL; Name: Standard Occupational Therapy; Assigned to Arm(s): Standard Occupational Therapy
D: Arm Label: Interprofessional Team Approach; Type: EXPERIMENTAL; Interventions: Other: Interprofessional Team Approach | Arm Label: Usual Home Care Services; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Interprofessional Team Approach; Assigned to Arm(s): Interprofessional Team Approach

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: ASPIS-Austrian Polyintervention Study to Prevent Cognitive Decline After Ischemic Stroke
Brief Summary: Aim of this randomized controlled study is to test if intensive polyintervention therapy including life style modifications targeting at reduction of modifiable risk factors of stroke can reduce the risk of post-stroke cognitive decline compared to a group of patients receiving standard care.


Options:
A: Arm Label: Robot group; Type: EXPERIMENTAL; Interventions: Device: robot-assisted neurocognitive therapy of hand function | Arm Label: Control group; Type: ACTIVE_COMPARATOR; Interventions: Other: Conventional neurocognitive rehabilitation | Intervention Type: DEVICE; Name: robot-assisted neurocognitive therapy of hand function; Assigned to Arm(s): Robot group | Intervention Type: OTHER; Name: Conventional neurocognitive rehabilitation; Assigned to Arm(s): Control group
B: Arm Label: animal assisted therapy; Type: EXPERIMENTAL; Interventions: Other: animal assisted therapy | Arm Label: standard therapy; Type: ACTIVE_COMPARATOR; Interventions: Other: standard therapy | Intervention Type: OTHER; Name: animal assisted therapy; Assigned to Arm(s): animal assisted therapy | Intervention Type: OTHER; Name: standard therapy; Assigned to Arm(s): standard therapy
C: Arm Label: Motivation and lifestyle intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Motivation and lifestyle intervention | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Motivation and lifestyle intervention; Assigned to Arm(s): Motivation and lifestyle intervention
D: Arm Label: CARET + CTI; Type: EXPERIMENTAL; Interventions: Behavioral: CARET, Behavioral: CTI | Arm Label: Sham CARET + Sham CTI; Type: SHAM_COMPARATOR; Interventions: Behavioral: Sham CARET, Behavioral: Sham CTI | Intervention Type: BEHAVIORAL; Name: CARET; Assigned to Arm(s): CARET + CTI | Intervention Type: BEHAVIORAL; Name: CTI; Assigned to Arm(s): CARET + CTI | Intervention Type: BEHAVIORAL; Name: Sham CARET; Assigned to Arm(s): Sham CARET + Sham CTI | Intervention Type: BEHAVIORAL; Name: Sham CTI; Assigned to Arm(s): Sham CARET + Sham CTI

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective, Double Blind Randomised Controlled Trial to Evaluate the Immunological Benefits and Clinical Effects of an Elimination Diet Using an Amino Acid Based Formula (AAF)
Brief Summary: The purpose of this study is to evaluate whether a new version of an amino acid based formula improves tolerance to milk in cow's milk allergic infants/young children.


Options:
A: Arm Label: Amino acid based infant formula; Type: ACTIVE_COMPARATOR; Interventions: Other: Amino acid based infant formula | Arm Label: Extensively hydrolyzed casein infant formula; Type: EXPERIMENTAL; Interventions: Other: Extensively hydrolyzed casein infant formula | Arm Label: Mother's own breast milk; Type: OTHER; Interventions: Other: Mother's own breast milk | Intervention Type: OTHER; Name: Amino acid based infant formula; Assigned to Arm(s): Amino acid based infant formula | Intervention Type: OTHER; Name: Extensively hydrolyzed casein infant formula; Assigned to Arm(s): Extensively hydrolyzed casein infant formula | Intervention Type: OTHER; Name: Mother's own breast milk; Assigned to Arm(s): Mother's own breast milk
B: Arm Label: Amino acid based formula; Type: ACTIVE_COMPARATOR; Interventions: Other: Special Medical Food | Arm Label: New amino acid based formula; Type: ACTIVE_COMPARATOR; Interventions: Other: Special Medical Food | Intervention Type: OTHER; Name: Special Medical Food; Assigned to Arm(s): Amino acid based formula | Intervention Type: OTHER; Name: Special Medical Food; Assigned to Arm(s): New amino acid based formula
C: Arm Label: parenteral nutrition solution; Type: OTHER; Interventions: Drug: Ped3CB | Intervention Type: DRUG; Name: Ped3CB; Assigned to Arm(s): parenteral nutrition solution
D: Arm Label: Amino Acid Formula; Type: EXPERIMENTAL; Interventions: Other: Amino Acid Formula | Arm Label: Amino Acid commercial formula; Type: ACTIVE_COMPARATOR; Interventions: Other: Amino Acid formula | Intervention Type: OTHER; Name: Amino Acid Formula; Assigned to Arm(s): Amino Acid Formula | Intervention Type: OTHER; Name: Amino Acid formula; Assigned to Arm(s): Amino Acid commercial formula

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicentre Randomised Placebo-controlled Study to Assess the Efficacy and Safety of a Single Administration of Ferric Carboxymaltose in Improving Fatigue Symptoms in Iron-deficient Non-anaemic Women of Child Bearing Age
Brief Summary: research study of Ferric carboxymaltose to treat fatigue/exhaustion symptoms, believed to be due to iron deficiency.


Options:
A: Arm Label: Injectafer; Type: EXPERIMENTAL; Interventions: Drug: Injectafer | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Injectafer; Assigned to Arm(s): Injectafer | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Ferinject ® (Ferric carboxymaltose) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Normal saline (0.9%) | Intervention Type: DRUG; Name: Ferinject ® (Ferric carboxymaltose); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Normal saline (0.9%); Assigned to Arm(s): 2
C: Arm Label: Ferinject; Type: EXPERIMENTAL; Interventions: Drug: Ferinject | Arm Label: Saline; Type: PLACEBO_COMPARATOR; Interventions: Other: Saline | Intervention Type: DRUG; Name: Ferinject; Assigned to Arm(s): Ferinject | Intervention Type: OTHER; Name: Saline; Assigned to Arm(s): Saline
D: Arm Label: Anemia; Type: ACTIVE_COMPARATOR; Interventions: Drug: Erythropoietin/Ferric carboxymaltose/Vitamin B12/Folic Acid | Arm Label: Iron deficiency; Type: ACTIVE_COMPARATOR; Interventions: Drug: Erythropoietin/Ferric carboxymaltose/Vitamin B12/Folic Acid | Arm Label: Natural comparison group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Erythropoietin/Ferric carboxymaltose/Vitamin B12/Folic Acid; Assigned to Arm(s): Anemia, Iron deficiency

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Secondary Prophylaxis of Hepatic Encephalopathy: A Double Blind, Randomized, Placebo Controlled Study With Supplementation With a Probiotic Preparation
Brief Summary: The aim of the proposed project is to study the effects of a probiotic preparation (VSL#3®) for the prevention of recurrence of HE (Hepatic encephalopathy) in patients after the recovery of an episode of overt HE (secondary prophylaxis)


Options:
A: Arm Label: Neomycin prescribed; Type: EXPERIMENTAL; Interventions: Drug: Neomycin | Arm Label: Probiotics (Lactobacillus casei rhamnosus, Lcr35) prescribed; Type: EXPERIMENTAL; Interventions: Drug: Lactobacillus casei rhamnosus (Lcr35) | Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Lactobacillus casei rhamnosus (Lcr35); Assigned to Arm(s): Probiotics (Lactobacillus casei rhamnosus, Lcr35) prescribed | Intervention Type: DRUG; Name: Neomycin; Assigned to Arm(s): Neomycin prescribed
B: Arm Label: VSL#3 placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: VSL#3 placebo | Arm Label: VSL#3 active probiotic; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: VSL#3 active probiotic | Intervention Type: DIETARY_SUPPLEMENT; Name: VSL#3 active probiotic; Assigned to Arm(s): VSL#3 active probiotic | Intervention Type: OTHER; Name: VSL#3 placebo; Assigned to Arm(s): VSL#3 placebo
C: Arm Label: Optimal Diet; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Optimal Diet | Arm Label: VSL#3; Type: EXPERIMENTAL; Interventions: Dietary Supplement: VSL#3® | Arm Label: AISA-5203-L; Type: EXPERIMENTAL; Interventions: Dietary Supplement: AISA-5203-L | Arm Label: Argan oil; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Argan oil | Intervention Type: BEHAVIORAL; Name: Optimal Diet; Assigned to Arm(s): Optimal Diet | Intervention Type: DIETARY_SUPPLEMENT; Name: VSL#3®; Assigned to Arm(s): VSL#3 | Intervention Type: DIETARY_SUPPLEMENT; Name: AISA-5203-L; Assigned to Arm(s): AISA-5203-L | Intervention Type: DIETARY_SUPPLEMENT; Name: Argan oil; Assigned to Arm(s): Argan oil
D: Arm Label: VSL#3; Type: EXPERIMENTAL; Interventions: Drug: VSL#3 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: VSL#3; Assigned to Arm(s): VSL#3 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized, Double-blind, Parallel-group, Placebo-controlled Study of Lanthanum Carbonate 750 to 2250 mg in Patients With Chronic Kidney Disease Not on Dialysis Who Develop Hyperphosphatemia
Brief Summary: The objective of this study is to investigate the efficacy and safety of lanthanum carbonate 750 to 2,250 mg in Japanese Chronic Kidney Disease Stage 3, 4 and 5 subjects not on dialysis.


Options:
A: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Fosrenol (Lanthanum Carbonate, BAY77-1931) | Arm Label: Arm 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Fosrenol (Lanthanum Carbonate, BAY77-1931); Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Arm 2
B: Intervention Type: DRUG; Name: Sevelamer hydrochloride; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: calcium acetate, Drug: atorvastatin | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: sevelamer, Drug: atorvastatin | Intervention Type: DRUG; Name: calcium acetate; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: sevelamer; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: atorvastatin; Assigned to Arm(s): 1, 2
D: Arm Label: PA21; Type: EXPERIMENTAL; Interventions: Drug: PA21 (2.5 g tablet containing 500 mg iron) | Arm Label: Sevelamer carbonate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sevelamer carbonate | Intervention Type: DRUG; Name: PA21 (2.5 g tablet containing 500 mg iron); Assigned to Arm(s): PA21 | Intervention Type: DRUG; Name: Sevelamer carbonate; Assigned to Arm(s): Sevelamer carbonate

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Varenicline and Smoking Cessation in Schizophrenia
Brief Summary: There is a strong association between smoking and schizophrenia with prevalence rates ranging from 74% to 90%, versus a national average of 30% in nonschizophrenic individuals. A number of hypotheses have been proposed to explain the relationship between high smoking rates and schizophrenia, mostly relating to self-medication primarily for the negative symptoms of schizophrenia. Smoking cessation rates among schizophrenic patients are considerably lower than for other psychiatric disorders. The negative health effects of smoking increase the morbidity and mortality in schizophrenic patients. Currently, the efficacy of bupropion HCl in the treatment of smoking by schizophrenic subjects is inconclusive, and there have not been any published studies of the efficacy of varenicline in schizophrenic subjects. As varenicline appears to be a promising treatment in non-psychiatric patients, it would be useful to expand these studies to examine its effects in schizophrenic patients. Identifying effective and safe means of smoking cessation for this vulnerable population has the potential to reduce morbidity and mortality among individuals with schizophrenia.


Options:
A: Arm Label: Selegiline Transdermal Patch; Type: ACTIVE_COMPARATOR; Interventions: Drug: Selegiline Transdermal Patch, Behavioral: Smoking Cessation Counseling | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Behavioral: Smoking Cessation Counseling | Intervention Type: DRUG; Name: Selegiline Transdermal Patch; Assigned to Arm(s): Selegiline Transdermal Patch | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BEHAVIORAL; Name: Smoking Cessation Counseling; Assigned to Arm(s): Placebo, Selegiline Transdermal Patch
B: Arm Label: Sugar Pill; Type: PLACEBO_COMPARATOR; Interventions: Other: Sugar Pill | Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Bupropion HCl; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion HCl | Intervention Type: OTHER; Name: Sugar Pill; Assigned to Arm(s): Sugar Pill | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Bupropion HCl; Assigned to Arm(s): Bupropion HCl
C: Arm Label: Varenicline and Placebo Patch; Type: PLACEBO_COMPARATOR; Interventions: Drug: Varenicline and Placebo Patch | Arm Label: Varenicline and Nicotine Patch; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline, Nicotine Patch | Intervention Type: DRUG; Name: Varenicline, Nicotine Patch; Assigned to Arm(s): Varenicline and Nicotine Patch | Intervention Type: DRUG; Name: Varenicline and Placebo Patch; Assigned to Arm(s): Varenicline and Placebo Patch
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2

Answer: B